Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT02489916

Donafenib Monotherapy for Previously Treated Metastatic Colorectal Cancer

Donafenib Monotherapy for Previously Treated Metastatic Colorectal Cancer: Multicentre, Open-label,Phase 1B Safety Study

Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Conditions Metastatic Colorectal Cancer

Interventions CM4307

Updated 5 times since 2017 Last updated: Jan 3, 2016 Started: Mar 31, 2014 Primary completion: Oct 31, 2015 Completion: Dec 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Metastatic Colorectal Cancer and is currently completed. Suzhou Zelgen Biopharmaceuticals Co.,Ltd leads this study, which shows 5 recorded versions since 2014 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Mar 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Data source: Suzhou Zelgen Biopharmaceuticals Co.,Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chengdu, China